Summit Therapeutics announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases

Reuters03-27
<a href="https://laohu8.com/S/SMMT">Summit</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases
  • Summit said updated Phase III data on ivonescimab in advanced non-small cell lung cancer will be presented as three posters at the European Lung Cancer Congress 2026 in Copenhagen on March 27, from 1:00 to 2:00 pm CET.
  • One poster from the HARMONi trial (NCT06396065) will report intracranial progression-free survival of 10.1 months with ivonescimab plus chemotherapy vs 6.5 months with chemotherapy in patients with baseline brain metastases (HR 0.53; nominal p=0.0068).
  • In HARMONi patients without baseline CNS metastases, intracranial progression-free survival was 15.7 months with ivonescimab plus chemotherapy vs 11.6 months with chemotherapy (HR 0.72; nominal p=0.0172).
  • Two additional posters will present health-related quality-of-life results from HARMONi and from HARMONi-2 (AK112-303; NCT05499390), which compared ivonescimab monotherapy vs pembrolizumab monotherapy in PD-L1 positive NSCLC in China.
  • The company said detailed HARMONi results were presented in September 2025 and that a biologics license application for the HARMONi setting was accepted for filing by the FDA in January 2026, with a PDUFA goal date of November 14, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260327933390) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment